Perfluorohexyloctane: uses, dosing, side effects & brands
Perfluorohexyloctane is a medicine sold in the U.S. under one brand, for dry eye syndromes. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Dry Eye Syndromes
- Available as
- Solution
- Sold as
- Miebo
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How perfluorohexyloctane is dosed
From the FDA label for Miebo (application NDA216675). Other perfluorohexyloctane products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Instill one drop of MIEBO four times daily into each eye. ( 2.1 ) 2.1 Recommended Dosage Instill one drop of MIEBO four times daily into affected eye(s). Contact lenses should be removed prior to and for at least 30 minutes after the administration of MIEBO. 2.2 Administration Instructions Step 1. Remove the cap from eye drop bottle. Step 2. Holding the bottle upright, gently squeeze the bottle. Step 3. While squeezing, turn the bottle upside down and release the pressure (drawing air into the bottle). Step 4. Keeping the bottle upside down, place the bottle above your eye and squeeze it again to release a drop into your eye. Repeat steps 1 - 4 for the second affected eye. Step 2. Step 3. Step 4.
Perfluorohexyloctane side effects
Most common ocular adverse reaction was blurred vision. Blurred vision was reported in less than 4% of individuals. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In patients with DED, 614 patients received at least one dose of MIEBO in two randomized controlled clinical trials across 68 sites in the United States. The most common ocular adverse reaction was blurred vision. Blurred vision and conjunctival redness were reported in 1-3% of individuals. In four premarketing studies (three open-label [n=127], one randomized [n=24 treated with at least one dose of perfluorohexyloctane]) the most common adverse reaction was hypersensitivity.
Who shouldn’t take perfluorohexyloctane
Hypersensitivity. ( 4.1 ) 4.1 Hypersensitivity MIEBO is contraindicated in patients with a history of hypersensitivity reaction to perfluorohexyloctane [see Adverse Reactions ( 6.1 )] .
Every perfluorohexyloctane product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Miebo.
What people report to the FDA about perfluorohexyloctane
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 23 reports naming perfluorohexyloctane, and the FDA flagged 48% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- dry eye4 reports
- fatigue4 reports
- dizziness3 reports
- headache3 reports
- inappropriate schedule of product administration3 reports
- anxiety2 reports
- covid-192 reports
- eye pain2 reports
Read these as a signal, not a rate. A report does not mean perfluorohexyloctane caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is perfluorohexyloctane?
MIEBO ® (perfluorohexyloctane ophthalmic solution) is a sterile, clear and colorless liquid containing 100% perfluorohexyloctane, for topical ophthalmic use. The active ingredient is 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane and is a semifluorinated alkane.
Can you take perfluorohexyloctane with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run perfluorohexyloctane against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does perfluorohexyloctane come in?
Across the brands we track, perfluorohexyloctane is currently marketed as solution, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic perfluorohexyloctane?
We do not currently list a generic-labelled perfluorohexyloctane product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Perfluorohexyloctane: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/perfluorohexyloctane
- MLA
- “Perfluorohexyloctane: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/perfluorohexyloctane.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for perfluorohexyloctane on DailyMed (NIH) ↗.